無料プレビュー

Verona Pharma plc (VRNA) · NASDAQ Global Market

プロフィール

Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced

主要指標

株価: $106.91 (+0.11%)
時価総額: 727億ドル
PER（今期予想）: 479.1
PBR: 42.0
配当利回り: —
52週レンジ: $31.09 – $106.93
業種: Healthcare / Biotechnology
上場: NASDAQ Global Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、BDX Becton, Dickinson and Company、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

更新: 2026-10-09